Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9395MR)

This product GTTS-WQ9395MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9395MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14295MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ104MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ8124MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ3701MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ7430MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ4656MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ3105MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ1125MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW